FDMT - 4D Molecular Therapeutics, Inc. Stock Price, Fair Value and News

$6.31+0.53 (+9.17%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FDMT Price Action

Last 7 days

-2.9%

Last 30 days

-25.0%

Last 90 days

-47.0%

Trailing 12 Months

-69.1%

FDMT RSI Chart

FDMT Valuation

Market Cap

328.1M

Price/Earnings (Trailing)

-2.29

Price/Sales (Trailing)

19.35

Price/Free Cashflow

-2.81

FDMT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FDMT Fundamentals

FDMT Revenue

Rev. Growth (Yr)

-99.99%

Rev. Growth (Qtr)

-40%

FDMT Earnings

Earnings (TTM)

-143.5M

Earnings Growth (Yr)

-327.49%

Earnings Growth (Qtr)

-25.43%

FDMT Profitability

Return on Equity

-25.95%

Return on Assets

-23.75%

Free Cashflow Yield

-35.59%

FDMT Investor Care

Shares Dilution (1Y)

37.25%

Diluted EPS (TTM)

-2.81

FDMT Alerts

JANUS HENDERSON GROUP PLC reported owning 6% of FDMT [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.2M	2.3M	22.0M	20.7M
2022	17.3M	2.8M	2.0M	3.1M
2021	14.7M	15.8M	16.9M	18.0M
2020	8.6M	10.3M	12.0M	13.6M
2019	0	0	0	7.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

CEO	Dr. David H. Kirn M.D.
WEBSITE	4dmoleculartherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	137

4D Molecular Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for 4D Molecular Therapeutics, Inc.? What does FDMT stand for in stocks?

FDMT is the stock ticker symbol of 4D Molecular Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 4D Molecular Therapeutics, Inc. (FDMT)?

As of Fri Dec 20 2024, market cap of 4D Molecular Therapeutics, Inc. is 328.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FDMT stock?

You can check FDMT's fair value in chart for subscribers.

Is 4D Molecular Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether FDMT is over valued or under valued. Whether 4D Molecular Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact 4D Molecular Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FDMT.

What is 4D Molecular Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, FDMT's PE ratio (Price to Earnings) is -2.29 and Price to Sales (PS) ratio is 19.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FDMT PE ratio will change depending on the future growth rate expectations of investors.